Condition: Cardiomyopathies · Genetic Predisposition · Cardiomyopathy, Primary · Sponsor: NHS Greater Glasgow and Clyde
Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging. This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.
This description comes directly from the study's public registry record.
Caroline J Coats, MBBS, PhD · 0141 451 6121 · Caroline.Coats@glasgow.ac.uk
Rachel C Myles, MBBS, PhD · 0141 451 6121 · Rachel.Myles@glasgow.ac.uk
Always discuss trial participation with your own doctor first.
| Queen Elizabeth University Hospital | Glasgow, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06446271